Research
    Xia Liangping
    Title Chief physician, doctoral advisor and Associate Chief for Department of Comprehensive Treatment
    Profile

    Prof. Xia Liangping specializes in formulation and analysis of comprehensive treatment strategies for common tumors, treatment and research of medical oncology, such as common intestinal cancer and lung cancer, as well as health care and management of VIP patients.

    Work experience
    1994-1996: Department of Surgery in the First Affiliated Hospital, Anhui Medical University;

    2002-present: Department of Comprehensive Treatment, Sun Yat-sen University Cancer Center

    Email
    Phone
    Research Interest(s)
    Education

    1989-1994: Department of Medicine, Anhui Medical University;
    1996-1999: The First Affiliated Hospital, Sun Yat-sen University (master's program);
    1999-2002: Sun Yat-sen University Cancer Center (doctoral program).

    Publications

    1. Chen ZY, He WZ, Peng LX, Jia WH, Guo RP, Xia LP, Qian CN.A prognostic classifier consisting of 17 circulating cytokines is a novel predictorLiao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014;7:1415-22.
    3. Jiang C, Liao FX, Rong RM, Yang Q, Yin CX, He WZ, Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pac J Cancer Prev. 2014;15(13):5493-8.
    4. He  WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, Chen XX, Rong RM, Zhang B, Xia LP. γ-Glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013 Aug;15(8):e443-52.. 
    5. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L. Initial Neutrophil Lymphocyte Ratio Is Superior To Platelet Lymphocyte Ratio As An Adverse Prognostic and Predictive Factor In Metastatic Colorectal Cancer. Medical Oncology. 2013 Mar;30(1):439.
    6. Wang F, He W, Qiu H, Wang X, Guo G, Chen X, Rong Y, Zhou F, Yin C, Yuan Z, Xia L. Lymph Node Ratio and pN Staging Show  FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352. 
    7. Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Wang F, Chen XX, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol. 2011; 17(43): 4839-4846.
    8. Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP*.Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity correlates with increase of Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 2011 Dec;28(4):1302-7.
    9. Xia LP, Qiu HJ, Chen XX, Hu PL, Guo GF, Wang F, Zhou FF, He WZ, Zhang B, Zhang L. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Med Oncol. 2011 Dec;28 Suppl 1:570-6.
    10. Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F.Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol. 2011 Dec;28 Suppl 1:197-203.
    11. Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, Wang F. Changes in Therapeutic Strategies in Chinese Male Patients with Breast Cancer: 40 Years of Experience in a Single Institute. Breast. 2010;19(6):450-5.
    12. Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352.
    13. Yin CX, Jiang C, Liao FX, Rong RM, He WZ,Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP.The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting. Chinese-German Journal of Clinical Oncology. 2014;13(4): 169-173.
    14. Zhang B, He WZ, Zhou FF, Guo GF, Jiang C, Yin CX,  Chen XX, Qiu HJ, Rong RM, Xia LP. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy,2013, 2:108. doi:10.4172/2167-7700.1000108
    15. Qiu HJ, He WZ, Yin CX, Guo GF, Wang F, Zhou FF, Jiang C, Xia LP. The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer. Chinese-German Journal of Clinical Oncology. 2012;11(10): 585-591.
    16. Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF , Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biology & Medicine. 2012;9(1):38-43.
    17. Wang F, Guo GF, Qiu HJ, Chen XX, Hui PL, Zhou FF, He WZ, Zhang B, Xia LP. Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer. Clin Oncol Cancer Res. 2011; 8(4): 235–241
    18. Qiu HJ, He WZ, Chen XX, Guo GF, Wang F, Zhou FF, Xia LP. The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. Chinese-German Journal of Clinical Oncology.2011;10(11): 621-625.
    19. Zhou FF,  Huang R, Jiang J, Wang F,  He WZ, Guo GF, Xia LP. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer. Chinese-German Journal of Clinical Oncology.2011;10(6): 311-316.
    20. Qiu HJ, Wang F, Guo GF, Zhou FF, He WZ, Xia LP. Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis. Chinese-German Journal of Clinical Oncology. 2011;10(3): 134-139.
    21. Wang F, Xia LP, Guo GF, Qiu HJ, Zhou FF, He WZ. The Pooled Analysis of Single Gemcitabine For Non-Small Cell Lung Cancer (NSCLC) Patients With Elderly Age. Chinese-German Journal of Clinical Oncology.2010;9(12):683-687.

    Guo Guifang
    Title Associate chief physician, advisor of master’s degree student and MD
    Profile

    Prof. Guo Guifang specializes in the medical treatment of such common tumors as intestinal cancer and lung cancer. She has delved into the treatment of intestinal cancer and presided over related state projects. She is adept at comprehensive treatment of common tumors. She has been engaged in diagnosis and treatment of VIP tumor patients for over ten years.

    Work experience
    1998-2001: General Hospital for Workers of Shanxi Coking Coal Group, resident physician;

    2004-present: Department of Comprehensive Treatment at Sun Yat-sen University Cancer Center, attending physician and associate chief physician.

    Email
    Phone
    Research Interest(s)
    Education

    1993-1998: Department of Clinical and Medical Treatment, Wannan Medical College (Undergraduate Program);

    2001-2004: Sun Yat-sen University Cancer Center (master program);

    2007-2010: Sun Yat-sen University Cancer Center (doctoral program);            

    2013-2014: University of Florida, the USA (Postdoctoral work for one year).

    Publications

    1.  Gui-fang Guo, Bei Zhang, Yu-chen Cai, Rui-hua Xu, Xu-xian Chen, Pei-li Hu,  Hui-juan Qiu, Fang Wang, Liang-ping Xia  Wen-qi Jiang. Autophagy-related Proteins Beclin-1 and LC3 Predicting Cetuximab Efficacy in Advanced Colorectal Cancer. World Journal of Gastroenterology. 2011 November 21;17(43):4741-4838.(IF=2.47)

    2. Gui-fang Guo, Yu-chen Cai, Bei Zhang, Rui-hua Xu, Hui-juan Qiu, Liang-ping Xia, Wen-qi Jiang, Pei-li Hu, Xu-xian Chen, Feifei Zhou, Fang Wang. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Medical Oncology. 2011 Dec;28 Suppl 1:S197-203. Epub 2010 Nov 17. (IF=2.205). 

    3. He WZ, Guo GF(共同第一作者), Yin CX, Jiang C, Wang F, Qiu HJ, Chen XX, Rong RM, Zhang B, Xia LP. Initial γ-glutamyl Transpeptidase Level Is A Novel Adverse Prognostic Factor In Human Metastatic Colorectal cancer. Colorectal Disease, 2013 Aug;15(8):e443-52. doi: 10.1111/codi.12258. (IF=2.58).

    4. Zheng Yan, Bei, Yuan-Yuan Huang, Hui-Juan Qiu, Liang-Ping Xia, Ping Chen1, Gui-Fang Guo* (Corresponding author). INVOLVEMENT OF AUTOPHAGY INHIBITION IN BRUCEA JAVANICA OIL EMULSION-INDUCED COLON CANCER CELL DEATH. Oncology Letters. (IF=1.0).

    5. Guifang Guo, Zheng Yan, Bei Zhang. Research of Brucea javanica against Cancer. Chinese journal of Integrative medicine.

    6. Ping Chen, Bei Zhang, Guifang Guo(Corresponding author), Liangping Xia, Huijuan Qiu. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. The Chinese-German Journal of Clinical Oncology. 2014,13

    7. Zhou FF, Xia LP, Guo GF, et al. Changes in Therapeutic Strategies in Chinese Male Patients with Breast Cancer: 40 Years of Experience in a Single Institute. Breast. 2010 May 20. (IF=2.155)

    8. Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP.Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity correlates with increase of Bax/Bcl-2 ratio in triple-negative breast cancer cells. Medical Oncology. (IF=2.205).

    9. Xia LP, Zhou FF, Guo GF, et al. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352.(IF=0.858)

    10. Xia LP, Guo GF, Zhang B, et al. Short-term Efficacy of Cetuximab-contained Regimen on Patients with Advanced Gastrointestinal (Noncolorectal) Cancer: Experiences of 16 Patients in Single Institute. Chinese-German Journal of Clinical Oncology.2009; 8(11):669-674.

    11. Xia LP, Guo GF, Qiu HJ, et al. Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. Chinese-German Journal of Clinical Oncology.2009;8(9):526-530.

    12. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L*. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.Med Oncol. 30(1):439-449. 2013. (IF=2.205)

    13. Wang F, Xia LP, Guo GF, et al. Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with Non-small cell lung cancer: a report of 6 cases. Chinese-German Journal of Clinical Oncology.2010;9(9):699-674.

    14. Xia LP, Rong YM, Guo GF, et al. Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publication. Chinese-German Journal of Clinical Oncology.2010;9(3):137-141.

    15. Xia LP, Zeng ZY, Guo ZM, Guo GF, Zhang B, Qiu HJ, Zhou FF. Neck dissection for recurrent and persistent lymph nodes of nasopharyngeal carcinoma after radiotherapy: effect and choice. Chinese-German Journal of Clinical Oncology.2009;8(2):81-85.

    16. Wang F, He W, Qiu H, Wang X, Guo G, Chen X, Rong Y, Zhou F, Yin C, Yuan Z, Xia L*. Lymph node ratio and pN staging show different superiority as prognostic predictors depending on the number of lymph nodes dissected in Chinese patients with luminal a breast cancer. Clin Breast Cancer. 12(6):404-11,2012. (IF=2.628) 

    17. Cai YC, Wang ZH, Sun TM, Shi YX, Guo GF, Sun YL, Wu MW, Huang PY, Li S, Jiang WQ. Diarylquinoline compounds induced autophagy-associated cell death though inhibiting Akt pathway and increasing reactive oxygen species in human nasopharyngeal carcinoma cells. Oncol Rep. 2013 Mar; 29(3): 983-992. (IF=2.191) 

    18. Chenxi Yin, Chang Jiang, Fangxin Liao, Yuming Rong, Xiuyu Cai, Guifang Guo, Huijuan Qiu, Xuxian Chen, Bei Zhang, Wenzhuo He, Liangping Xia. Initial LDH level can predict the survival benefit from bevacizumab in  the first-line setting in Chinese patients with metastatic colorectal cancer. OncoTargets and Therapy.2014,7,1415-1422. (IF=1.342)

Where are we | Contact us

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.